The editorial TLDR.
Anti-Müllerian hormone (AMH) is produced by the small, immature follicles in your ovaries — the resting pool waiting to mature each cycle. A higher AMH suggests a larger reserve of those resting follicles; a lower AMH suggests a smaller one. The number gives a rough snapshot of the size of your ovarian reserve at a single point in time.
Most U.S. labs report AMH in nanograms per milliliter (ng/mL). A typical reference band for premenopausal adult women runs roughly 1.0–4.0 ng/mL, with values dropping gradually with age and approaching zero around menopause. PCOS often pushes AMH meaningfully above the upper end of the range — sometimes well over 6 ng/mL — because there are more small follicles than usual.
What AMH is not — and where most marketing gets it wrong — is a predictor of fertility, time to conception, or whether you will be able to have a baby. AMH says something about how many eggs are left; it says little about their quality, when you will ovulate, or whether a given cycle will result in pregnancy. Women with low AMH conceive naturally all the time. Women with high AMH sometimes struggle. As always, what you do with the number is a conversation worth having with a qualified women's-health clinician or fertility specialist.
What AMH actually is.
Anti-Müllerian hormone is a glycoprotein produced by the granulosa cells that surround small, growing follicles in the ovary — specifically, the pre-antral and small antral follicles, which are the pool of eggs being primed for the next several cycles but not yet recruited for ovulation. Each cycle, one of those small follicles gets selected to mature, ovulates, and the rest go through atresia. AMH reflects the size of that resting pool.
Because AMH comes from the resting follicles rather than the dominant cycling follicle, levels are remarkably steady across a single menstrual cycle. That's the practical advantage AMH has over older markers like FSH: it doesn't need to be timed to cycle day. You can draw it on day 4 or day 22 and get a comparable result.
"AMH is a number about quantity, not quality. It tells you how big the pool is — not what's swimming in it."
AMH levels rise through adolescence, peak in the early-to-mid twenties, then decline gradually through the thirties and more steeply through the forties. By the menopause transition, AMH typically approaches the limit of detection on standard assays. The trajectory is broadly predictable at a population level — but with significant individual variation. Some women in their early forties have AMH levels similar to women in their late twenties; some women in their late twenties have AMH levels more typical of the early forties. That variation is exactly why AMH is informative as one data point, and exactly why it's a poor predictor on its own.
Standard U.S. labs measure AMH with an automated immunoassay (commonly the Roche Elecsys or Beckman Access platforms). The results are usually in ng/mL, but you may also see pmol/L on international reports — the conversion is roughly 1 ng/mL ≈ 7.14 pmol/L. Cross-laboratory comparisons should be made with care.
Why AMH matters for women.
AMH has become the U.S. fertility industry's most-marketed biomarker — partly because it's easy to test, partly because it produces a tidy single number, and partly because it lends itself to anxiety-driven sales. A more careful read of the literature suggests AMH is useful in three specific clinical conversations and almost useless in a fourth.
Estimating ovarian reserve before fertility treatment. AMH is one of the inputs reproductive endocrinologists use to estimate how a woman's ovaries are likely to respond to ovarian stimulation in IVF — how many follicles are likely to develop, what dose of medication to use. Here, the number is genuinely informative. It's used alongside antral follicle count on ultrasound and age.
Identifying PCOS. Women with PCOS often have AMH levels well above the typical reference range, sometimes more than double, because they have more small antral follicles than usual. AMH isn't a standalone diagnostic criterion for PCOS in the U.S., but recent international guidelines (Rotterdam, 2023 update) accept AMH as a substitute for the ultrasound criterion in adult women, when measured on a validated assay. In practice, very high AMH alongside irregular cycles and androgen excess is a recognizable PCOS pattern.
Estimating proximity to menopause. A very low AMH in the late thirties or forties — particularly below 0.5 ng/mL — suggests the menopause transition may be closer than average. The number is not a precise countdown, but it is part of a clinical picture that includes cycle changes, FSH and estradiol patterns.
Predicting natural fertility or time to pregnancy — this is where AMH is most often misused. Multiple large studies, including the Time to Conceive study published in JAMA, have found that AMH does not meaningfully predict whether a healthy woman will conceive naturally within a given timeframe. Low AMH does not mean low fertility now; high AMH does not guarantee easy conception. AMH is a quantity marker, not a quality marker — and conception depends on egg quality, partner factors, tubal patency, hormonal timing and many other things AMH cannot see.
Egg freezing decisions. AMH is often used as one input into the conversation about whether and when to consider elective oocyte cryopreservation. It is a useful conversation; the marketing around it sometimes is not.
What the ranges generally mean.
Most U.S. labs report AMH in ng/mL. Reference ranges vary by laboratory and assay, and change substantially with age; the broad shape below is for premenopausal adult women under 35.
AMH reference, premenopausal women
ng / mLIllustrative ranges, not diagnostic. Reference ranges drop with age and vary by laboratory and assay. Always discuss your specific result with a qualified healthcare provider.
What may drive AMH low or high.
The patterns below come up most often when AMH reads outside the expected band for a woman's age.
What may drive AMH low.
- Age. The single biggest factor. AMH declines gradually through the thirties and steeply through the forties.
- Approaching menopause. A very low AMH in the late thirties or forties, alongside cycle shortening or skipping, can signal proximity to the menopause transition.
- Diminished ovarian reserve (DOR). A clinical pattern where ovarian reserve is lower than expected for age. Sometimes idiopathic; sometimes linked to genetic or autoimmune factors.
- Primary ovarian insufficiency (POI). Ovarian function decline before age 40. AMH is typically very low; FSH typically elevated.
- Past chemotherapy, radiation or ovarian surgery. Treatments and procedures that affect the ovaries can reduce AMH, sometimes substantially.
- Hormonal contraception. Combined OCPs and the LNG-IUD suppress measured AMH. Re-test off contraception for fertility conversations.
- Vitamin D deficiency. Several studies have linked very low vitamin D status with lower AMH — worth checking alongside.
What may drive AMH elevated.
- Polycystic ovary syndrome. The most common cause of high AMH in U.S. women of reproductive age. The high small-follicle count drives the number.
- Functional hypothalamic patterns with polyfollicular ovaries. Less common but worth distinguishing from classical PCOS.
- Assay differences. Different laboratory platforms can produce different AMH values from the same blood. Trends within one lab are more interpretable than cross-lab comparisons.
- Granulosa cell tumors. Rare. Worth ruling out with extremely elevated AMH outside the typical PCOS pattern.
Why AMH alone shouldn't drive big life decisions.
Low AMH does not mean you cannot conceive naturally. High AMH does not mean you will. The single most important thing to know about AMH is that it has been studied extensively as a predictor of natural fertility and found to be a poor one — including in large prospective cohorts.
AMH is a useful number alongside age, antral follicle count, FSH, estradiol and clinical history — particularly when fertility treatment is being planned, when PCOS is being investigated, or when proximity to menopause is part of the question. It is a snapshot of a pool, not a forecast of a pregnancy.
Questions worth asking your healthcare provider.
Conversation starters, not a script. These are designed to make sure the AMH conversation is read in context — not as a single number used to drive an expensive decision:
- How should I read my AMH in light of my age — and what does it actually tell us about my reserve?
- Could we pair AMH with cycle-day-3 FSH, estradiol and (if relevant) an antral follicle ultrasound?
- If I'm on hormonal contraception, how does that affect the AMH reading, and should we re-test off it?
- What does my AMH say about fertility specifically — and what doesn't it say?
- If my AMH is high alongside irregular cycles, could PCOS be part of the picture?
- When should we recheck, and what changes in symptoms or cycle would prompt earlier review?
Your provider will guide the conversation based on your full medical context. These prompts are designed to keep AMH where it belongs — as one informative number in a wider picture, not as a verdict.
When to test, and how it's measured.
The AMH test is a standard venous blood draw. Unlike FSH or estradiol, AMH is steady across the menstrual cycle and does not need to be timed to a particular cycle day — any day works.
If you are taking combined oral contraception, the levonorgestrel IUD or other hormonal therapy, mention it on the requisition. These can suppress measured AMH by 20–30%; many fertility specialists prefer to re-test after at least two to three months off hormonal contraception when the conversation is fertility-focused. If you are taking high-dose biotin (often in hair, skin and nail supplements), pause it for at least 48 hours before any hormonal panel — biotin can interfere with several immunoassays.
AMH is typically ordered alongside cycle-day-3 FSH and estradiol when fertility is on the table. For PCOS workups, it sits alongside total and free testosterone, SHBG, DHEA-S, fasting insulin and lipids. Always read AMH in the context of your age, your cycle history and your clinical picture — not as a single number on a screen.
Direct-to-consumer at-home tests — Modern Fertility, LetsGetChecked, Function Health and others — include AMH in their fertility-focused panels. They're useful for a baseline; they don't replace the clinical conversation. For the trade-offs across services, see our guide to at-home blood tests for women.